The incidence of invasive fungal diseases (IFDs) has increased in the past decades as a consequence of the ever-growing population of immunocompromised patients (with a solid organ transplant \[SOT\] or hematopoietic stem cell transplant) or patients receiving advanced critical care \[[@OFW128C1]--[@OFW128C4]\]. Aside from *Pneumocystis jirovecii*, the most common threats are *Candida* spp and *Aspergillus* spp, but a large variety of other opportunistic fungal pathogens can cause severe diseases in vulnerable patients. A key to a favorable prognosis of these deadly infections is early initiation of an accurate antifungal therapy, which itself relies on early diagnosis. Nonetheless, diagnosis of both common and rare IFD remains challenging, partly due to the limited availability of sensitive early diagnostic markers.

Among possible markers, (1-3)-β-[d]{.smallcaps}-glucan (BG), an abundant cell wall polysaccharide found in a majority of fungi \[[@OFW128C5]\], has been used more and more frequently in the last 5 years \[[@OFW128C6], [@OFW128C7]\]. It has been proposed as an early biomarker of IFD and is included in diagnostic criteria of IFD in the 2008 version of European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) \[[@OFW128C6]\]. However, this marker cannot discriminate the various fungi that can cause IFD.

Different studies have evaluated clinical performance of the BG assay. Some focused on specific target populations (ie, hematological patients \[[@OFW128C8]\], intensive care unit \[ICU\] patients \[[@OFW128C9], [@OFW128C10]\], or the pediatric population \[[@OFW128C11]\]) or on specific IFD types (candidemia \[[@OFW128C10], [@OFW128C12]\] or invasive aspergillosis \[IA\] \[[@OFW128C8]\]), whereas others included all kinds of patients with all kinds of IFD \[[@OFW128C13], [@OFW128C14]\]. They reported wide discrepancies on sensitivity (40%--100%) and specificity (45%--99%) of the assay \[[@OFW128C7], [@OFW128C15], [@OFW128C16]\], probably due to the heterogeneity of their designs. Other studies have analyzed diagnostic utility of serial BG sampling before diagnosis of IFD \[[@OFW128C17]--[@OFW128C20]\], with some of them emphasizing its value as an early IFD marker, especially in invasive candidiasis (IC) \[[@OFW128C10], [@OFW128C17], [@OFW128C18], [@OFW128C20]\]. Finally, a few other research groups have attempted to interpret postdiagnosis kinetics of BG levels \[[@OFW128C18], [@OFW128C20]--[@OFW128C23]\]. Nonetheless, the use of this marker in clinical practice remains problematic \[[@OFW128C24]\].

In the present study, we sought to assess BG serum levels in patients who received a diagnosis of various types of IFD (proven or probable; including IC or IA, as well as a panel of rare IFD). To obtain useful clinical information, we evaluated the rate of BG positivity when the diagnosis was made (time of diagnosis \[TOD\]) and analyzed the kinetics of serum BG levels during antifungal treatment and its relation to prognosis.

PATIENTS AND METHODS {#s2}
====================

Hospital and Patients {#s2a}
---------------------

Necker-Enfants Malades is a teaching hospital, where adults and children at high risk for IFD receive medical care. From January 2011 to July 2015, we carried out an observational study on BG testing performed in the mycology laboratory at the request of clinicians from various hospital wards. In the logs of the laboratory, we identified all patients (adults and children) with documented fungal infections (except for pneumocystosis) who had at least 1 sample analyzed for BG at the TOD (TOD being a time interval around the day of diagnosis, ie, the date of collection of the sample allowing diagnostic; see below).

From this list, we first selected a group of patients with IC, which included (1) patients with a positive culture from a normally sterile site (including blood cultures, joint fluid aspiration, vertebral or cardiac biopsy) and a BG sample collected between 1 day before and 7 days after the first positive culture was drawn and (2) patients with chronic disseminated candidiasis (ie, hepatosplenic candidiasis) diagnosed as possible IFD on the basis of a typical computed tomography (CT) scan, according to EORTC/MSG diagnostic criteria (6) and for whom a BG sample was taken between 7 days before and after the CT scan, which first showed microabscesses compatible with the diagnosis.

From the same original list, we then selected patients with probable or proven IA diagnosed according to the EORTC/MSG criteria (6), except that we extended the definition of probable IA to patients in whom real-time PCR detected deoxyribonucleic acid of *Aspergillus fumigatus* in a normally sterile sample (ie, serum, cerebrospinal fluid, or biopsy) \[[@OFW128C25], [@OFW128C26]\]. For IA, the patients selected had a BG sample taken between 3 days before and 7 days after the day of diagnosis. In case of slowly evolving IA, such as bone infections, the delay was extended to 15 days after the day of diagnosis.

Finally, from the same list, we selected patients with rare IFD defined as patients with deep-seated, invasive, or chronic infections due to fungi other than *Candida* and *Aspergillus*, with histopathological evidence or a positive culture of normally sterile material (biopsy or needle aspiration of a sterile site, or blood culture). For rare IFD, the patients selected had a BG sample taken between 7 days before and 10 days after the day of diagnosis.

For all 3 types of IFD cases, all BG test results (that were requested by the clinicians after the initial BG assay) were also analyzed and defined as "BG follow-up." Patients known to have another IFD diagnosed within 1 month before or after the diagnosis of the IFD under study, or those receiving intravenous immunoglobulins (IVIG), were excluded from the analysis. This study was approved by the local ethics committee (record 20160310).

(1-3)-β-[d]{.smallcaps}-Glucan Antigen Detection {#s2b}
------------------------------------------------

All BG testing was performed at the request of treating physicians by means of the Fungitell assay (Associates of Cape Cod, Inc., Falmouth, MA). Each sample was tested in duplicate, and the mean of 2 values was considered a definitive result, except when duplicates differed by more than 20%, in which case the test was repeated. We used the recommended positive cutoff value of 80 pg/mL and recorded all positive results up to 523 pg/mL. Higher results were recorded as \>523 pg/mL. None of the samples were diluted.

Data Collection and Analysis {#s2c}
----------------------------

Patients\' charts were reviewed, and we collected patients\' demographic and general data (hospital ward, immunocompromised status) and clinical data related to the IFD (use of antifungal drugs 2 weeks before IFD, antifungal treatment after diagnosis, neutropenia \[ie, neutrophil count \<1500 cells/µL\], the presence of a central venous catheter, assessment of IFD extent, outcome, and medical procedures or treatments known as a possible cause of false-positive BG results \[albumin use, a surgical procedure, mucositis, digestive graft-versus-host disease, or hemodialysis\]).

We performed the statistical analyses using the R software (version 3.2.2; <http://www.cran.r-project.org>). Univariate analysis was conducted using 2-sided Pearson\'s, Fisher\'s exact, and Student\'s *t* tests (α = 0.05). Variables with univariate *P* values \<.25 were included in multivariate analyses, which were conducted using descending stepwise logistic regression. The logistic models were tested for statistical stability using the RVAideMemoire package (<http://cran.r-project.org/web/packages/RVAideMemoire/>). To analyze BG negativation kinetics, we performed survival analysis using Kaplan--Meier estimates.

RESULTS {#s3}
=======

Invasive Candidiasis {#s3a}
--------------------

Forty-nine patients with candidiasis were included. As shown in Table [1](#OFW128TB1){ref-type="table"}, 41 had candidemia, with associated deep-seated localizations in 11. The remaining 8 had IC (endocarditis, osteoarthritis, or chronic disseminated candidiasis) without concomitant candidemia. Overall, cultures were positive in 43 of 49 patients, with *Candida albicans* being the most common (19 of 43, 44%) of the 11 species isolated (Table [1](#OFW128TB1){ref-type="table"}). Among the 41 cases of candidemia, 15 (36.5%) tested negative for BG (\<80 pg/mL) at the TOD (Table [1](#OFW128TB1){ref-type="table"}). There were no differences between patients with negative or positive BG test results at the TOD in terms of the patients\' category (see Table [1](#OFW128TB1){ref-type="table"}), time of BG sampling, antifungal drug use before candidemia, vascular catheterization at the TOD, outcome, and a possible cause of false-positive BG (Table [2](#OFW128TB2){ref-type="table"}). By contrast, patients with *C. albicans* candidemia were significantly more likely to have a positive BG result at the TOD (15 of 16) than did patients with candidemia due to another *Candida* species (9 of 25; multivariate odds ratio = 25.4; 95% confidence interval, 3.6--560.3; *P* \<.01) (Table [2](#OFW128TB2){ref-type="table"}). Of note, patients with *C. albicans* candidemia had deep-seated localizations (8 of 16) more frequently than those with non-*C. albicans* candidemia (4 of 25), but the difference was not significant (data not shown). Table 1.Demographics, Clinical Characteristics, and Mycological Data of the Patients With Invasive Candidiasis at the Time of DiagnosisPatient IDAgeGenderCategory of PatientSample Providing Diagnosis*Candida* Species/Diagnostic ElementLocation of CandidiasisDuration of Candidemia (Days)BG at TODTime Interval Between Sample Providing Diagnosis and BG Sample (Days)BG Value (pg/mL)123MHematologyBlood culture*Candida lusitaniae*Blood32267272MHematologyBlood culture*Candida krusei*Blood1−1\>523341FHematologyBlood culture*Candida glabrata*Blood33\<80446MHematologyBlood culture*Candida tropicalis*Blood12\>523559MHematologyBlood culture*C. glabrata*Blood43\<80661MHematologyBlood culture*Candida guilliermondii*Blood5−1\<80776MHematologyBlood culture*C. glabrata*Blood20471864FHematologyBlood culture*Candida albicans*Blood10156962FHematologyBlood culture*C. guilliermondii*Blood1−1\<801051FHematologyBlood culture*C. krusei*Blood631161146MHematologyBlood culture*C. guilliermondii*Blood22\<801268MHematologyBlood culture*Candida norvegensis*Blood5−1\<801374MHematologyBlood culture*C. albicans*Blood412781461FHematologyBlood culture*C. norvegensis*Blood32\<801575MHematologyBlood culture*C. albicans*Blood13\<801677MHematologyBlood culture*C. albicans*Blood122331730MHematologyBlood culture*C. albicans*Blood41\>5231856MSOTBlood culture*Candida parapsilosis*Blood121311965MSOTBlood culture*C. parapsilosis*Blood43\>5232070FSOTBlood culture*C. parapsilosis*Blood15872144FSOTBlood culture*C. tropicalis*Blood102602214FPediatric ICUBlood culture*Kodamaea ohmeri*Blood36\<80230MPediatric ICUBlood culture*C. albicans*Blood123722417FPediatric ICUBlood culture*C. albicans*Blood14100252MPediatric ICUBlood culture*C. albicans*Blood25\>523262MPediatric ICUBlood culture*C. parapsilosis*Blood13\<80276FPediatric ICUBlood culture*Hyphopichia burtonii*Blood22\<80281FPediatric ICUBlood culture*C. lusitaniae*Blood27\<80291FPediatric ICUBlood culture*C. tropicalis*Blood13216302MPediatric ICUBlood culture*C. guilliermondii*Blood12\<803175MHematologyBlood culture*C. albicans*Blood, Urine124283212MPediatric ICUBlood culture*C. lusitaniae*Blood, Urine13\<80332MPediatric ICUBlood culture*C. albicans*Blood, Urine42179347MPediatric ICUBlood culture*C. krusei*Blood, Ascites17\<803564FHematologyBlood culture*C. glabrata*; *C. krusei*Blood, Abdominal abscess11−1367364FPediatric ICUBlood culture, Pericardial fluid*C. albicans*Blood, Sternum, Mediastinum,37973742FHematologyBlood culture*C. albicans*Blood, Brain62\>5233866MHematologyBlood culture*C. albicans*Blood, Brain504113963FHematologyBlood culture*C. albicans; Candida kefyr*Blood, Intestine34\>5234034MHematologyBlood culture*C. albicans*Blood, Liver, Spleen, Kidney12\>5234131MHematologyBlood culture*C. albicans*Blood, Liver, Spleen, Kidney10460420FPreterm neonateJoint fluid aspiration*C. albicans*Multifocal osteoarthritis, Eyena7\>5234381MAuto-immune disorderBone biopsy*C. albicans*Spondylodiscitisna42744427MSickle Cell AnemiaHeart valve*C. albicans*Heartna−6^a^1174555MHematologyCT scan^b^MicroabscessesLiver, Spleenna12604655FHematologyCT scan^b^MicroabscessesLiver, Spleenna3\>5234753MHematologyLiver MRIMicroabscessesLiverna−43484856MHematologyCT scan^b^MicroabscessesLiver, Spleen, Kidneyna2\>5234923FHematologyCT scan^b^MicroabscessesLiverna1373[^1][^2][^3] Table 2.Comparison of Demographic and Clinical Characteristics of the Patients With Candidemia Who Tested Positive vs Negative for BG at the Time of DiagnosisTotal (N = 41)Patients With Negative BG at TOD (n = 15) (%)Patients With Positive BG at TOD (n = 26) (%)*P* Value^a^Multivariate OR^b^*Pa*^b^Socio-demographic data Gender  Female166 (40.0)10 (38.5)1.00  Male259 (60.0)16 (61.5) Average age (years) \[range\]40.6 \[0; 77\]34.5 \[1--75\]44.2 \[0--77\].28Medical data Category of patient  ICU pediatric patients137 (46.7)6 (23.1).171.00.09  Hematology or Renal transplant adult patients288 (53.3)20 (76.9)4.7 \[0.9--36.4\] *Candida* species responsible for candidemia  Non-albicans *Candida* species2514 (93.3)11 (42.3)\<.011.00.01*  Candida albicans*161 (6.7)15 (57.7)25.4 \[3.6--560.3\] Median time interval between blood culture sampling and yeast growth (hours) \[range\]31 \[10--67\]29 \[15--60\]34 \[10--67\].67 Median duration of candidemia (days) \[range\]2 \[1--11\]2 \[1--5\]1.5 \[1--11\].64 Use of catheter at time of 1st positive blood culture3914 (93.3)25 (96.2)1.00 Positive culture of catheter114 (26.7)7 (28.0).75 Systemic antifungal drugs before candidemia176 (40.0)11 (42.3)1.00 Outcome  Positive2513 (86.7)12 (46.2).02---  Worsening (invasive candidiasis and/or death within 30 d)162 (13.3)14 (53.8) Median time interval between candidemia and 1st BG sampling (day) \[range\]2 \[−3;7\]3 \[−1;7\]2 \[−3;7\].21--- Neutropenia at time of candidemia226 (40.0)16 (61.5).21--- Albumin during 1 mo before candidemia31 (6.7)2 (8.0)1.00 Surgery within 15 d before candidemia82 (13.3)6 (23.1).69 Mucitis or digestive GVH disease within 15 d before candidemia155 (33.3)10 (38.5)1.00 Hemodialysis within 15 d before candidemia81 (6.7)7 (26.9).22---[^4][^5][^6]

In 21 of 41 (51%) patients with candidemia, BG were also tested 2 to 7 days before the first positive blood culture was drawn. Seven (33%) tested positive for BG, 5 of whom had an associated deep-seated localization (data not shown). (1-3)-β-[d]{.smallcaps}-glucan follow-up was available for 27 of 41 (66%) patients, for 1--9 weeks ([Supplementary Table 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1)). Of those 27, 5 had persistently negative BG test results ("negative profile", [Supplementary Table 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1)) and 6 alternating negative or low BG results ("unreliable kinetic profile"). Among the 16 of 27 (59%) remaining patients, who had positive BG kinetics, 5 (31%) had a rapid decrease in the BG level after the diagnosis (over half decrease in \<7 days, and negativation in less than 1 month, "rapid BG decrease profile"), whereas 11 (69%) had persistently high BG test results (over half BG decrease in more than 15 days, and negativation in more than 1 month, "slow BG decrease profile"). Examples of these BG postdiagnosis kinetic profiles are presented in [Supplementary Figure 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1).

We observed a trend (*P* = .04) toward more frequent deep-seated localizations (central nervous system, kidney, liver, mediastinum, deep abscesses) associated with candidemia in patients with slow decrease profiles versus those with rapid decrease profiles (data not shown).

All 8 patients with IC without candidemia (1 case of endocarditis relapse, 2 osteoarthritis, and 5 chronic disseminated candidiasis) had positive BG at the TOD (Table [1](#OFW128TB1){ref-type="table"}). In 3 of the patients for whom a BG follow-up was available, BG values remained high for more than 6 weeks ([Supplementary Table 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1)).

Invasive Aspergillosis {#s3b}
----------------------

Forty-five patients with IA (32 \[71%\] probable and 13 \[29%\] proven IA) were included in the study. Thirty-two (71%) had a pulmonary IA, in 8 of them, associated with secondary locations (sinus, brain, skin, or pharynx), and 13 (29%) had extrapulmonary IA (ear, sinus, brain, meninges, cranium, skin, aorta, or vertebra). The patients\' characteristics are given in Table [3](#OFW128TB3){ref-type="table"}. Table 3.Demographics, Clinical Characteristics, and Mycological Data of the Patients With Invasive Aspergillosis at the Time of DiagnosisPatient IDAgeGenderCategory of PatientSample (Test) Providing Initial Diagnosis*Aspergillus* SpeciesGM Ag at TOD (Index)Location of IAEORTC/MSG IA ClassificationBG at TODTime Interval Between Sample Providing Diagnosis and BG Sample (Days)BG Value (pg/mL)128FHematologySerum (PCR)*Aspergillus fumigatus*0.55LungProbable080238MHematologySerum (GM Ag)*A. fumigatus*0.72LungProbable0\<80373MHematologySerum (GM Ag)---0.73LungProbable0\<80480FHematologySerum (GM Ag)---1LungProbable1\<80529FHematologySerum (GM Ag)---1.18LungProbable0\<80663FHematologySerum (GM Ag)*A. fumigatus*0.56LungProbable−3467769FHematologySerum (GM Ag)---0.67LungProbable0\<80830FHematologySerum (GM Ag)---0.54LungProbable0\<80963MHematologySerum (GM Ag)*A. fumigatus*0.51LungProbable−3\<801054FHematologySerum (PCR)*A. fumigatus*1.15LungProbable0991163FHematologyBAL (Culture)*A. fumigatus*0.5LungProbable3\<801220MHematologySerum (GM Ag)*A. fumigatus*0.64LungProbable01311323MHematologySerum (PCR)*A. fumigatus*0.27LungProbable−2\>523140MHematologyLung biopsy (Culture)*A. fumigatus*NdLungProven−2\<801551MHematologySerum (GM Ag)---1.69LungProbable4\<801661MHematologySerum (GM Ag)*A. fumigatus*0.84LungProbable01291746FHematologySerum (GM Ag)*A. fumigatus*1.13LungProbable0\<801876MHematologySerum (PCR)*A. fumigatus*5.63LungProbable0\<801967MHematologySerum (GM Ag)---0.61LungProbable0\<802073FHematologySerum (PCR)*A. fumigatus*1.9LungProbable01762153MSOT, HematologyBronchoaspiration (Culture)*A. fumigatus*0.06LungProbable−5^a^1132260MSOTLung biopsy (Culture)*A. fumigatus*NdLungProbable7\<802371FSOTSerum (GM Ag)---1.3LungProbable53492462MHematologySerum (PCR)*A. fumigatus*0.44LungProbable0\<802522MHematologyUvula biopsy (Culture)*A. fumigatus*0.23Lung, PharynxProven1\<802647FHematologySerum (GM Ag)---1.8Lung, SinusProbable0832757MHematologySerum (GM Ag)*A. fumigatus*0.64Lung, SinusProbable02572855FHematologySerum (GM Ag)---4.61Lung, SinusProbable0\>5232942MSOTSerum (PCR)*A. fumigatus*NdLung, BrainProbable3\>5233074MSOT, HematologyCSF (PCR)*A. fumigatus*NdLung, Sinus, BrainProbable0\<803165MHematologySerum (GM Ag)---2.04Lung, Sinus, BrainProbable0\<803251MSOTSkin biopsy (Culture)*A. fumigatus*0.09Lung, Brain, SkinProven43773356MSOTCSF (PCR)*A. fumigatus*NdAorta, Skin, BrainProbable1\>5233461MHematologySerum (GM Ag)---1.44BrainProbable0953563FHematologySinus biopsy (Culture)*Aspergillus flavus*0.22SinusProven0\<803674MNon-ICSinus biopsy (Culture)*A. fumigatus*0.17Sinus, Eye socketProven2\<803772MSOTCSF (PCR)*A. fumigatus*0.11Sinus, BrainProbable62783856MNon-ICSinus biopsy (Culture)*A. fumigatus*NdSinus, BrainProven−3\<803919MNon-ICSinus biopsy (Culture)*A. flavus*0.1Sinus, Cranium, BrainProven11\>5234076MDiabetesSinus biopsy (Culture)*A. fumigatus*NdEar, MeningesProven73284171MDiabetesSinus biopsy (Culture)*A. flavus*0.3Ear, Sinus, CraniumProven14\<804274FDiabetesClivus biopsy (Culture)*A. flavus*0.18Ear, CraniumProven121604368FDiabetesMeningeal biopsy (Culture)*A. flavus*0.06Ear, Cranium, MeningesProven131184468MNon-ICVertebral biopsy (Culture)*Aspergillus terreus*1.06VertebraProven3\>5234519MNon-ICVertebral biopsy (Culture)*A. terreus*0.18VertebraProven0440[^7][^8]

At the TOD, 22 of 45 (48%) were BG negative (Table [3](#OFW128TB3){ref-type="table"}). When comparing the groups of patients with negative and positive BG test results at the TOD, we did not observe differences in the categories of the patients (see Table [3](#OFW128TB3){ref-type="table"}), the location or classification of IA, the time of BG sampling, the antifungal drug use before the diagnosis, neutropenia status of the patients, 6- or 12-week survival, or the possible cause of false-positive BG results ([Supplementary Table 2](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1)).

In 14 of 45 (31%) IA patients, BG were measured 4 to 15 days before TOD, and the results were positive in 5 cases (data not shown). (1-3)-β-[d]{.smallcaps}-glucan follow-up was available for 37 of 45 (82%) patients for periods ranging from 1.5 to 29 weeks ([Supplementary Table 3](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1)). Of the 37 patients with BG follow-up, 7 were persistently BG negative, 5 had variable positive/negative BG test results, and 25 were repeatedly BG positive ([Supplementary Table 3](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1)). Among these 25, BG levels decreased rapidly in 7 (28%), with negativation within 1 month after the TOD, whereas in 14 (56%) patients, BG results were still positive after 3 months ([Supplementary Figure 2](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1)). Examples of BG postdiagnosis kinetic profiles are presented in Figure [1](#OFW128F1){ref-type="fig"}. When comparing patients with rapid versus slow BG negativation in terms of type and location of IA and survival, we did not observe significant differences, except for a trend toward slower BG negativation in patients with sinus and/or brain IA (*P* = .05; data not shown). Figure 1.Examples of the 4 main categories of (1-3)-β-[d]{.smallcaps}-glucan (BG) postdiagnosis kinetic profiles observed after a diagnosis of invasive aspergillosis (IA). For each example, the blue curve represents the BG kinetics before, at the time, and after a diagnosis of IA. The red cross represents the day of collection (D0) of the first biological sample that led to the diagnosis of IA: y-axis, BG values in pg/mL; x-axis, time relative to the day (D0) of collection of the sample that led to the diagnosis of IA, expressed in weeks. (A) Negative BG profile (N = 8 of 37): patients showing persistently negative BG test results after IA diagnosis. The kinetics shown are those of Patient 19 (hematology patient), who received a diagnosis of probable pulmonary IA, for whom 3 BG assays were performed before diagnosis and 6 BG assays were performed within 12 weeks of diagnosis. The first mycological result allowing for the diagnosis of probable IA was the detection of serum galactomannan antigens. (B) Unreliable BG profile (N = 5 of 37): patients showing alternating negative or low BG test results after IA diagnosis. The kinetics shown are those of Patient 2 (hematology patient), who received a diagnosis of probable pulmonary IA, for whom 2 BG assays were performed before diagnosis and 8 BG assays were performed within 16 weeks of diagnosis. The first mycological result allowing for diagnosis of probable IA was the detection of serum galactomannan antigens. (C) Rapid BG decrease profile (N = 6 of 37): patients with positive BG kinetics after IA diagnosis, who showed a rapid decrease in the BG level, with BG negativation in less than 1 month. The kinetics shown are those of Patient 7 (hematology patient), who received a diagnosis of probable pulmonary IA, for whom 2 BG assays were performed before diagnosis and 8 assays were performed within 13 weeks of diagnosis. The first mycological result allowing for diagnosis of probable IA was the detection of serum galactomannan antigens. (D) Slow BG decrease profile (N = 14 of 37): patients with positive BG kinetics after IA diagnosis, who showed persistently elevated BG levels for more than 3 months. The kinetics shown are those of Patient 32 (solid organ transplant), who received a diagnosis of proven multisite IA, for whom 15 BG assays were performed within 33 weeks of diagnosis. The first mycological result allowing for diagnosis of proven IA was a culture of a skin biopsy that tested positive for *Aspergillus fumigatus*.

Rare Invasive Fungal Diseases {#s3c}
-----------------------------

The 49 patients with rare IFD were classified into 18 diagnoses including cryptococcosis (N = 10); mucormycosis (N = 6); fusariosis, scedosporiosis, and trichosporonosis (N = 4 each); eumycotic mycetoma (N = 5); and invasive subcutaneous phaeohyphomycosis (N = 3). The patients\' characteristics are presented in Table [4](#OFW128TB4){ref-type="table"}. Table 4.Demographics, Clinical Characteristics, and Mycological Data of Patients With Rare Invasive Fungal DiseasesIFD due to Rare FungiAgeGenderCategory of PatientSample Providing DiagnosisDiagnostic ElementLocation of Fungal InfectionBG at TODTime Interval Between Sample Providing Diagnosis and BG Sample (Days)BG Value (pg/mL)Cryptococcosis5FNon-ICBlood culture*Cryptococcus neoformans*Blood, Meninges, Lymph nodes6\<8055FHematologyCSF*C. neoformans*Meninges124457MHIVCSF*C. neoformans*Blood, Meninges, Urine4\<8056FSOTSerumPositive cryptococcal EIA antigenMeninges, Skin, Urine08943MSOTSputum*C. neoformans*Lung5\<8048FSOTCSF*C. neoformans*Meninges1\<8060MHIVPulmonary biopsyEncapsulated yeasts at Grocott stainingLung−134218FHematologyBlood culture*C. neoformans*Blood−1\<8062MSOTCSF*C. neoformans*Meninges0\<8017FSOTCSF*C. neoformans*Meninges8\<80Zygomycosis69FSOTCutaneous biopsy*Mucor irregularis*Skin and subcutaneous tissue61444FSOTGastric biopsy*Lichtheimia* spGastrointestinal tract115822MHematologySinus biopsy*Rhizopus* spSinus013466FHematologySinus biopsy*Lichtheimia ramosa*Sinus−1\<808FSOTCutaneous biopsy; Serum*Rhizopus oryzae*Skin and subcutaneous tissue10\<80IFD due to *Fusarium* sp70FHematologyBlood culture*Fusarium solanii*Blood29961FSOTSputum*Fusarium* spLung0\<8042MHematologyBlood culture*Fusarium* spBlood10\<8062FHematologyBlood culture*Fusarium proliferatum*Blood0\<80IFD due to *Trichosporon* sp33MHematologyBlood culture*Trichosporon* spBlood1\>52367FHematologyBlood culture*Trichosporon* spBlood9\>52310FICUBlood culture*Trichosporon asahii*Blood6\<80IFD due to *Rhodotorula* sp3MICUBlood culture*Rhodotorula mucilaginosa*Blood41842MHematologyBlood culture*R. mucilaginosa*Blood5\<80IFD due to *Geotrichum* sp72MHematologyBlood culture*Geotrichum capitatum*Blood0287IFD due to *Malassezia* sp4MHematologyBlood culture*Malassezia furfur*Blood3\<80IFD due to *Acremonium* sp63MHematologyBlood culture*Acremonium strictum*Blood0\<80Infection due to *Trichoderma* sp67FSOTBAL*Trichoderma longibrachiatum*Lung3489IFD due to *Exophiala* sp8FHematologyCSF*Exophiala dermatitidis*Brain, Meninges−3\>523IFD due to *Cladophialophora* sp6MNon-ICCSF*Cladophialophora bantiana*Brain6145IFD due to *Rasamsonia* sp29MHematologyCutaneous abscess*Rasamsonia argillacea*Lung, Skin, Subcutaneous tissue1\<80Histoplasmosis43FHIVBone marrow aspiration*Histoplasma capsulatum*Bone marrow, Lymph nodes, Skin223336FHIVBone marrow aspiration*H. capsulatum*Disseminated3255Coccidioidomycosis32MNon-ICSputum*Coccidioides immitis*Lung (relapse)0^a^150IFD due to *Scedosporium* sp69FSOTBone biopsy*Scedosporium apiospermum*Lung, Bone, Eye, Blood2\>52314MHematologySputum*Scedosporium prolificans*Lung, Blood1\<8032MCystic fibrosisSputum*Scedosporium* spBone (relapse), Disseminated7^b^27052FSOTCutaneous sample*S. apiospermum*Subcutaneous tissue, Bone0\<80Invasive cutaneous phaeohyphomycosis62MSOTCutaneous biopsy*Alternaria infectoria*Skin, Subcutaneous tissue0\>52358FSOTCutaneous biopsy*Alternaria rosea*Skin, Subcutaneous tissue−429863MSOTCutaneous biopsy*Phialemonium dimorphosporum*Skin, Subcutaneous tissue3\>523Deep dermatophytosis72MSOTCutaneous biopsy*Trichophyton rubrum*Skin, Subcutaneous tissue−215156MSOTCutaneous biopsy*T. rubrum*Skin, Subcutaneous tissue1\>523Eumycotic mycetoma34MNon-ICCutaneous biopsy*Madurella mycetomatis*Lumbar subcutaneous tissue, Lung, Pleura, Retroperitoneum0^c^25459MSOTCutaneous biopsyNonidentified black fungusSubcutaneous tissue1^d^30469MDiabetesCutaneous biopsy*Exophiala jeanselmei*Subcutaneous tissue030568MSOTCutaneous biopsy*F. solanii*Subcutaneous tissue033754MSOTGrains in seropurulent exudateNonidentified fungusSubcutaneous tissue0237[^9][^10][^11][^12][^13]

Overall, 19 (39%) of the patients with rare IFD were BG negative at the TOD. We observed great variability of BG positivity at the TOD in almost every category of rare IFD, except for the 10 patients with chronic subcutaneous IFD (including phaeohyphomycosis, deep dermatophytosis, or eumycotic mycetoma) who were all BG positive at the TOD. A BG follow-up was available for 4 of these 10 patients, and their BG results remained positive for over 25 weeks after the TOD. Unexpectedly, 3 of 10 patients with cryptococcosis (1 pulmonary case and 2 meningeal cases) and 3 of 6 patients with mucormycosis (1 subcutaneous case, 1 intestinal, and 1 sinus case) were BG positive at the TOD.

DISCUSSION {#s4}
==========

Our study, which aimed at assessing BG serum levels at TOD and BG follow-up kinetics in patients treated for documented IFD, has resulted in several significant findings.

First, we observed a relatively low BG positivity rate at the TOD in the 2 most common IFD, candidemia and IA, as well as in rare IFD. Indeed, only 64%, 52%, and 61% of patients who received a diagnosis of candidemia, probable/proven IA, or rare IFD tested positive for BG at the TOD, respectively. These findings confirmed the results of other studies reporting low BG sensitivity in different IFD and various patient populations \[[@OFW128C13]--[@OFW128C15], [@OFW128C19]\]. For instance, Koo et al \[[@OFW128C13]\] and Ostrosky-Zeichner et al \[[@OFW128C14]\], who both analyzed the BG assay performance at the TOD regardless of the category of patients or type of IFD, observed an average sensitivity of 64%. Koo et al \[[@OFW128C13]\] reported even lower BG sensitivity at the TOD among patients receiving a hematopoietic stem cell transplant or patients with febrile neutropenia (43% and 38%, respectively) \[[@OFW128C13]\]. It is noteworthy that the BG positivity rate observed at the TOD in patients who received a diagnosis of candidemia in our study was somehow lower than the ones previously reported; other authors, including Ostrosky-Zeichner et al \[[@OFW128C14]\], reported sensitivity rates above 80% \[[@OFW128C27], [@OFW128C28]\]. This lack of positive BG test results at the TOD observed in every type of IFD is casting doubt on the usefulness of BG detection for early diagnosis of IFD. Thus, the BG serial sampling proposed in some works \[[@OFW128C17], [@OFW128C20], [@OFW128C29], [@OFW128C30]\] to help anticipate IFD diagnosis in at-risk patients might be effective only for a minority of patients, which remains to be determined.

Among patients with candidemia, we did not find medical risk factors associated with BG positivity at the TOD (eg, vascular catheterization, prior antifungal drug use, or an already known possible cause of false-positive BG results), but we observed differences strongly related to the *Candida* species involved. Indeed, we found that BG is a more reliable diagnostic marker in cases of candidemia due to *C. albicans* than to other *Candida* species. To our knowledge, this finding has not been reported previously. Ostrosky-Zeichner et al \[[@OFW128C14]\] stated that the BG assay may be less sensitive for *Candida parapsilosis* than for other *Candida* species, but this notion was not confirmed by Martínez-Jiménez \[[@OFW128C27]\], who observed good sensitivity of BG testing in cases of candidemia due to *C. parapsilosis*, even better than for *C. albicans*. Because most *Candida* infections are caused by endogenous *Candida* strains colonizing the patients before the infection \[[@OFW128C31], [@OFW128C32]\], a procedure of BG serial sampling may thus be worthwhile (targeting patients at risk of candidemia and known to be colonized by *C. albicans* or hospitalized in wards reporting high prevalence of *C. albicans* infections). Regarding the BG evolution in patients with candidemia who tested positive for BG at the TOD, we observed very different patterns of BG dynamics. In one third of the cases, the BG levels decreased rapidly after initiation of treatment (a significant decrease in 1 week), whereas in the other cases (two thirds), the BG level was persistently elevated during at least 2 weeks after the IFD diagnosis. It is worth mentioning that patients with slow BG decrease profiles were more likely to have candidemia associated with deep-seated infected sites. Furthermore, patients with IC not associated with candidemia, in particular patients with chronic disseminated candidiasis, also showed persistently elevated serum BG levels. These findings are consistent with the results of other studies suggesting that a decrease in BG levels after treatment initiation is a marker of a favorable prognosis, especially in IC \[[@OFW128C20], [@OFW128C22], [@OFW128C23], [@OFW128C33]\]. Jaijakul et al \[[@OFW128C22]\] observed a decrease in BG levels among patients who received successful treatment of candidemia, whereas patients with tissue infection or treatment failure showed persistently elevated BG levels. Altogether, these results should encourage clinicians to evaluate BG kinetics in patients with positive BG test results at the TOD of candidemia or in patients with suspected deep-seated candidiasis, in particular chronic disseminated candidiasis. Complementary prospective studies focusing on BG kinetics during treatment would be useful in this regard.

As for IA, we did not find a significant association between the level of BG at TOD and the status of the patient (immunocompromised or not), the type of aspergillosis (location or EORTC/MSG classification), or the outcome. On the other hand, as in candidemia, only one third of the patients with positive BG at the TOD had a rapid BG decrease profile (negativation within 1 month), whereas two thirds showed a very slow BG decrease, with negativation often observed more than 100 days after the diagnosis. This very slow BG evolution, which might be as lengthy as or even longer than the therapeutic protocol itself, may limit the use of BG serial sampling for monitoring the clinical course in cases of IA \[[@OFW128C18], [@OFW128C19]\]. Nevertheless, in the absence of a tangible improvement after treatment initiation, persistently elevated or rising BG levels 1 month after the diagnosis may warn clinicians about a possible treatment failure \[[@OFW128C18], [@OFW128C19]\]. Further studies in this area are necessary to evaluate the real efficacy of such a strategy.

Regarding BG detection in rare IFD, we observed a relatively low frequency of positive BG results at the TOD, but we noticed an exception. In cases of chronic subcutaneous IFD (phaeohyphomycosis, deep dermatophytosis, or eumycotic mycetoma), all patients tested positive for BG at the TOD, and we observed extremely slow BG decrease after the diagnosis (BG persistently positive for more than 25 weeks). This result may be linked to the chronic and relatively indolent progression of this type of infections, with often delayed diagnosis \[[@OFW128C34]\]. Thus, our findings suggest that BG may be a useful diagnostic marker of chronic subcutaneous IFD. Although we expected all patients with cryptococcosis and mucormycosis to test negative for BG at the TOD \[[@OFW128C6], [@OFW128C35]\], some of them tested positive. Such findings have already been reported regarding cryptococcosis \[[@OFW128C36], [@OFW128C37]\]. Rhein et al \[[@OFW128C37]\], who observed 89% sensitivity of a BG assay in cerebrospinal fluid of patients with cryptococcal meningitis, suggested that due to the low reactivity of *Cryptococcus* species with the BG test \[[@OFW128C38]\] (presumably due to BG\'s low concentration in the *Cryptococcus* cell wall), the success of BG detection during cryptococcosis may depend on the fungal burden during the infection. For mucormycosis, however, none of the studies involving patients with this type of IFD showed BG positivity at the TOD \[[@OFW128C13], [@OFW128C14], [@OFW128C19], [@OFW128C36]\]. Positive BG test results in our cases of mucormycosis may be associated, as suggested above, with the substantial fungal burden. These positive test results may also be a consequence of a yet unknown cross-reactivity of the BG assay. Indeed, if we had assessed the main causes of BG false-positivity in our study (IVIG, albumin injection, hemodialysis, or a recent surgical procedure), we might have missed less frequent causes, such as concomitant infection due to *Nocardia* \[[@OFW128C39]\] or even unknown causes.

CONCLUSIONS {#s5}
===========

Overall, our study, which included many categories of patients (hematology, SOT, ICU, and even non-immunocompromised patients), suggests that BG detection in the serum of at-risk patients is not as effective as an early diagnostic marker of IFD. Nonetheless, our findings also indicate that this marker may help to assess the risk of chronic infection after the initial IFD diagnosis, and, in particular, serial BG sampling may facilitate the evaluation of the risk of disseminated candidiasis associated with candidemia. Taken together, our results offer valuable information on clinical utility of the BG assay in various IFD and underscore the difficulties with interpretation of BG data in clinical settings.

Supplementary Data {#s6}
==================

[Supplementary material](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw128/-/DC1) is available online at *Open Forum Infectious Diseases online* (<http://OpenForumInfectiousDiseases.oxfordjournals.org/>).
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[^1]: Abbreviations: BG, (1-3)-β-[d]{.smallcaps}-glucan antigens; CT, computed tomography; ICU, intensive care unit; ID, identification; MRI, magnetic resonance imaging; na, not applicable; SOT, solid organ transplant; TOD, time of diagnosis.

[^2]: ^a^ The diagnosis of endocarditis was made 2 months after fungemia due to *C. albicans* without deep-seated localization.

[^3]: ^b^ Abdominal CT scan.

[^4]: Abbreviations: BG, (1-3)-β-[d]{.smallcaps}-glucan antigens; GVH, graft-vs-host; ICU, intensive care unit; OR, odds ratio; TOD, time of diagnosis.

[^5]: ^a^ Univariate analyses were performed using Pearson χ^2^, Fisher exact, Wilcoxon, or Student *t* tests (α = 0.05).

[^6]: ^b^ All variables with *P* values \<.25 were included for multivariate descending stepwise logistic regression.

[^7]: Abbreviations: BG, (1-3)-β-[d]{.smallcaps}-glucan; CSF, cerebral spinal fluid; EORTC/MS, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GM Ag, galactomannan antigens; IA, invasive aspergillosis; Nd, not determined; Non-IC, non-immunocompromised; PCR, polymerase chain reaction; SOT, solid organ transplant; TOD, time of diagnosis.

[^8]: ^a^ An exception was made regarding the inclusion of this patient, even though his/her first BG was sampled 5 days before mycological diagnosis.

[^9]: Abbreviations: BG, (1-3)-β-[d]{.smallcaps}-glucan; BAL, bronchoalveolar lavage; CSF, cerebral spinal fluid; EIA, enzyme immunoassay; HIV, human immunodeficiency virus; ICU, intensive care unit; IFD, invasive fungal diseases; Non-IC, non-immunocompromised; SOT, solid organ transplant; TOD, time of diagnosis.

[^10]: ^a^ The initial diagnosis of pulmonary coccidioidomycosis was performed 21 months before the current relapse.

[^11]: ^b^ The initial diagnosis of spondylodiscitis due to *Scedosporium* sp was performed 4 years before the current relapse.

[^12]: ^c^ The initial diagnosis of the eumycotic mycetoma was performed 13 years before the current onset.

[^13]: ^d^ The initial diagnosis of the eumycotic mycetoma was performed 24 years before the current onset.
